ArsenalBio Secures $325M in Oversubscribed Series C Round

San Francisco, CA, September 4, 2024 (Business Wire) -- Arsenal Biosciences, a clinical-stage company focused on developing advanced CAR T-cell therapies for solid tumors, has raised $325 million in an oversubscribed Series C financing round. The funding, which attracted new investors such as ARCH Venture Partners and Regeneron Ventures, will be used to advance ArsenalBio's programmable cell therapy programs through clinical development. Existing investors, including the Parker Institute for Cancer Immunotherapy and Bristol-Myers Squibb, also participated, reflecting strong confidence in ArsenalBio's innovative approach to cancer treatment.

Read full article here.